Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo matching with BMS-188667 Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

NCT01142726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 28, 2026, 5:51 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 28, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

NCT01350804
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo, Abatacept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
44
States / cities
Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 28, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 28, 2026, 5:51 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 28, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 28, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

NCT00442611
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 28, 2026, 5:51 PM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Sep 28, 2026, 5:51 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 28, 2026, 5:51 PM EDT